SG11201811640SA - Multispecific antigen binding proteins and methods of use thereof - Google Patents

Multispecific antigen binding proteins and methods of use thereof

Info

Publication number
SG11201811640SA
SG11201811640SA SG11201811640SA SG11201811640SA SG11201811640SA SG 11201811640S A SG11201811640S A SG 11201811640SA SG 11201811640S A SG11201811640S A SG 11201811640SA SG 11201811640S A SG11201811640S A SG 11201811640SA SG 11201811640S A SG11201811640S A SG 11201811640SA
Authority
SG
Singapore
Prior art keywords
nanjing
jiangsu
antigen binding
district
international
Prior art date
Application number
SG11201811640SA
Other languages
English (en)
Inventor
Chuan-Chu Chou
Yafeng Zhang
Shu Wu
Zhenyu Liu
Zhongdao Li
Fangliang Zhang
Original Assignee
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotech Co Ltd filed Critical Nanjing Legend Biotech Co Ltd
Publication of SG11201811640SA publication Critical patent/SG11201811640SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
SG11201811640SA 2016-07-20 2017-07-20 Multispecific antigen binding proteins and methods of use thereof SG11201811640SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/090703 WO2018014260A1 (fr) 2016-07-20 2016-07-20 Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
PCT/CN2017/093644 WO2018014855A1 (fr) 2016-07-20 2017-07-20 Protéines de liaison aux antigènes multispécifiques et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11201811640SA true SG11201811640SA (en) 2019-02-27

Family

ID=60992747

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811640SA SG11201811640SA (en) 2016-07-20 2017-07-20 Multispecific antigen binding proteins and methods of use thereof

Country Status (14)

Country Link
US (2) US11447573B2 (fr)
EP (1) EP3487887A4 (fr)
JP (2) JP7115991B2 (fr)
KR (1) KR20190040483A (fr)
CN (1) CN109476762A (fr)
AU (1) AU2017300349A1 (fr)
BR (1) BR112019000970A2 (fr)
CA (1) CA3030933A1 (fr)
EA (1) EA201990331A1 (fr)
IL (1) IL264211A (fr)
MX (1) MX2019000730A (fr)
SG (1) SG11201811640SA (fr)
WO (2) WO2018014260A1 (fr)
ZA (1) ZA201900181B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
EP3619235A1 (fr) 2017-04-11 2020-03-11 Inhibrx, Inc. Constructions polypeptidiques multispécifiques comprenant une liaison cd3 contrainte et leurs méthodes d'utilisation
MX2020001198A (es) 2017-08-04 2020-09-07 Genmab As Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
KR20200104333A (ko) 2017-12-28 2020-09-03 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 단일-도메인 항체 및 이의 변이체
WO2019134710A1 (fr) * 2018-01-08 2019-07-11 Nanjing Legend Biotech Co., Ltd. Protéines de liaison aux antigènes multispécifiques et leurs procédés d'utilisation
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
WO2019179390A1 (fr) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Nouvelles molécules d'anticorps anti-pd-1/egfr bispécifiques
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN111566127A (zh) * 2018-03-27 2020-08-21 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
EP3774917A4 (fr) 2018-03-30 2022-01-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique contre lag-3 et leurs utilisations
CN110357966A (zh) * 2018-04-09 2019-10-22 非同（成都）生物科技有限公司 具有延长的半衰期和增强的抗肿瘤效果的双特异性抗体
WO2019228406A1 (fr) * 2018-05-29 2019-12-05 Wuxi Biologics (Shanghai) Co., Ltd. Nouvel anticorps bispécifique anti-cd3/anti-cd20
CN112399973B (zh) * 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
CA3105454A1 (fr) 2018-07-03 2020-01-09 Catalent Pharma Solutions, Llc Molecules proteiques multifonctionnelles comprenant de la decorine et utilisation associee
CN110835375B (zh) * 2018-08-16 2021-04-06 上海洛启生物医药技术有限公司 一种抗pd-1/egfr双特异性抗体及其用途
EP3864045A2 (fr) * 2018-10-11 2021-08-18 Inhibrx, Inc. Anticorps à domaine unique dll3 et compositions thérapeutiques
CN113166261A (zh) * 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
CN111378044B (zh) * 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP3946354A4 (fr) * 2019-03-28 2023-01-11 Ab Studio Inc. Protéines hétéromultimères et leurs méthodes d'utilisation
US20220289848A1 (en) * 2019-05-17 2022-09-15 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof
CN114008080B (zh) * 2019-06-12 2023-06-09 南京金斯瑞生物科技有限公司 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
US20220267475A1 (en) * 2019-06-25 2022-08-25 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereof
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用
CN113968910A (zh) * 2019-07-11 2022-01-25 武汉友芝友生物制药有限公司 四价对称双特异性抗体
WO2021008577A1 (fr) * 2019-07-16 2021-01-21 南京金斯瑞生物科技有限公司 Anticorps bispécifique anti-cd47/anti-ctla-4, son procédé de préparation et son utilisation
CN114206940B (zh) * 2019-07-23 2023-09-22 南京金斯瑞生物科技有限公司 抗cd47/抗lag-3双特异抗体及其制备方法和应用
WO2021097800A1 (fr) * 2019-11-22 2021-05-27 Abl Bio Inc. Anticorps multispécifiques anti-pd-l1/anti-b7-h3 et leurs utilisations
WO2021178263A1 (fr) * 2020-03-05 2021-09-10 Merck Sharp & Dohme Corp. Bibliothèques d'affichage de domaine variable d'anticorps de chaîne lourde de type humain (vhh)
CN113637082A (zh) 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
CN113968909A (zh) * 2020-07-22 2022-01-25 信达生物制药(苏州)有限公司 一种双特异性抗体的纯化方法
CN114146174A (zh) * 2020-07-24 2022-03-08 信达生物制药(苏州)有限公司 抗pd-l1/ox40双特异性抗体制剂及其制备方法和用途
CN111944052B (zh) * 2020-08-26 2022-02-11 中国药科大学 抗TNF-α/PD-1双特异性抗体及其应用
WO2022048625A1 (fr) * 2020-09-04 2022-03-10 Nanjing GenScript Biotech Co., Ltd. Anticorps multispécifiques ciblant la protéine de spicule du sars-cov-2 et son utilisation
EP4247424A1 (fr) * 2020-11-18 2023-09-27 Suzhou Transcenta Therapeutics Co., Ltd. Molécules bi-fonctionnelles
EP4247850A1 (fr) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Compositions de car-t double segmenté et méthodes pour l'immuno-cancérothérapie
KR20230126718A (ko) * 2020-12-30 2023-08-30 우시 바이올로직스 아일랜드 리미티드 다중특이적 항원 결합 단백질
CN114573704B (zh) * 2021-03-10 2022-11-01 北京拓界生物医药科技有限公司 Pd-1/ctla-4结合蛋白及其医药用途
TW202330626A (zh) * 2021-09-30 2023-08-01 大陸商貝達藥業股份有限公司 雙特異性抗體及其應用
WO2024032664A1 (fr) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 Anticorps ciblant pd-l1 et vegf et son utilisation
WO2024036271A1 (fr) * 2022-08-12 2024-02-15 The Johns Hopkins University Constructions d'anticorps multiparatopiques anti-pd-l1 et leurs utilisations

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
CA1338518C (fr) 1987-09-23 1996-08-13 Joyce M. Zarling Heteroconjugues d'anticorps pour tuer les cellules infectees par le vih
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
CA2149329C (fr) 1992-11-13 2008-07-15 Darrell R. Anderson Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
CA2258518C (fr) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Molecules de reconnaissance ayant une interaction specifique avec le site actif ou la fissure d'une molecule cible
AU7298398A (en) 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
EP1051493A2 (fr) 1998-01-26 2000-11-15 Unilever Plc Procede servant a preparer des fragments d'anticorps
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
EP2829609A1 (fr) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Anticorps CTLA-4 humains et leurs utilisations
EP1229125A4 (fr) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk Procede de production d'un polypeptide
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1276849A4 (fr) 2000-04-12 2004-06-09 Human Genome Sciences Inc Proteines fusionnees a de l'albumine
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424602C (fr) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1419179T3 (da) 2001-08-10 2010-06-21 Univ Aberdeen Antigenbindingsdomæner fra fisk
WO2003025020A1 (fr) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Procede pour creer une banque d'anticorps de chameaux
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CA2481837A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
EP1513879B1 (fr) 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (fr) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anticorps anti-p-selectine
EP1864998B2 (fr) 2004-07-22 2022-06-22 Erasmus University Medical Center Rotterdam Molécules de liaison
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1791565B1 (fr) 2004-09-23 2016-04-20 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
CA2612355A1 (fr) * 2005-06-16 2006-12-28 Virxsys Corporation Complexes d'anticorps
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RU2515108C2 (ru) * 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP5184374B2 (ja) 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
WO2007112940A2 (fr) 2006-03-31 2007-10-11 Ablynx N.V. Séquence d'acides aminés dérivée de l'albumine, son utilisation pour augmenter la demi-vie de protéines thérapeutiques et d'autres composés et entités thérapeutiques, et produits de recombinaison qui la comprennent
CA2651567A1 (fr) 2006-05-09 2007-11-22 Genentech, Inc. Polypeptides de liaison a squelettes optimises
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
EP2650311A3 (fr) 2007-11-27 2014-06-04 Ablynx N.V. Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
IT1394281B1 (it) * 2009-01-19 2012-06-06 Zardi Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti.
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
CA2756244A1 (fr) 2009-04-02 2010-10-07 Roche Glycart Ag Anticorps multispecifiques renfermant des anticorps de longueur entiere et des fragments fab a chaine unique
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PT2954779T (pt) 2009-12-10 2019-05-29 Regeneron Pharma Ratinhos que produzem anticorpos de cadeia pesada
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
JP5987053B2 (ja) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
WO2014138314A1 (fr) * 2013-03-05 2014-09-12 Baylor College Of Medicine Virus oncolytique
WO2014209804A1 (fr) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Anticorps bispécifiques
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US20150273033A1 (en) * 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
SG11201607203XA (en) 2014-03-21 2016-09-29 Regeneron Pharma Non-human animals that make single domain binding proteins
ES2921875T3 (es) 2014-08-11 2022-09-01 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
WO2016081384A1 (fr) * 2014-11-17 2016-05-26 Genentech, Inc. Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
IL293719B2 (en) 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CN109310766A (zh) 2016-02-26 2019-02-05 伊蒙纽斯私人有限公司 多特异性分子
WO2017165681A1 (fr) 2016-03-24 2017-09-28 Gensun Biopharma Inc. Inhibiteurs trispécifiques pour le traitement du cancer
CN107400166A (zh) 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
WO2019134710A1 (fr) * 2018-01-08 2019-07-11 Nanjing Legend Biotech Co., Ltd. Protéines de liaison aux antigènes multispécifiques et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3487887A1 (fr) 2019-05-29
US11447573B2 (en) 2022-09-20
JP2022136261A (ja) 2022-09-15
MX2019000730A (es) 2019-06-20
AU2017300349A1 (en) 2019-02-14
KR20190040483A (ko) 2019-04-18
CA3030933A1 (fr) 2018-01-25
JP2019524693A (ja) 2019-09-05
IL264211A (en) 2019-02-28
WO2018014855A1 (fr) 2018-01-25
BR112019000970A2 (pt) 2019-04-30
JP7115991B2 (ja) 2022-08-09
CN109476762A (zh) 2019-03-15
EA201990331A1 (ru) 2019-06-28
EP3487887A4 (fr) 2020-03-25
US20190202935A1 (en) 2019-07-04
WO2018014260A1 (fr) 2018-01-25
US20230059836A1 (en) 2023-02-23
ZA201900181B (en) 2023-04-26

Similar Documents

Publication Publication Date Title
SG11201811640SA (en) Multispecific antigen binding proteins and methods of use thereof
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201901126UA (en) Combination therapy for cancer
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201803676PA (en) Site specific her2 antibody drug conjugates
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201906410YA (en) Method and apparatus for adjusting screen luminance, terminal device and storage medium
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201900361RA (en) Methods of treating prostate cancer
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201903602RA (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
SG11201906682YA (en) Glucagon receptor binding proteins and methods of use thereof
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates